Oppenheimer restated their market perform rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research report released on Monday, Benzinga reports. The brokerage currently has a $19.00 target price on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on ACAD. Mizuho cut shares of ACADIA Pharmaceuticals from […]